Mitral Valve Disease Market By Treatment Type (Mitral Valve Repair, Mitral Valve Replacement, Cardiac Resynchronization Therapy, Mitral Valve Therapeutics), By Indication (Mitral Valve Stenosis, Mitral Valve Prolapse, Mitral Valve Regurgitation), By End U

Mitral Valve Disease Market By Treatment Type (Mitral Valve Repair, Mitral Valve Replacement, Cardiac Resynchronization Therapy, Mitral Valve Therapeutics), By Indication (Mitral Valve Stenosis, Mitral Valve Prolapse, Mitral Valve Regurgitation), By End User (Hospitals, Ambulatory Surgical Centers, Others): Global Opportunity Analysis and Industry Forecast, 2022-2031

The Mitral Valve Disease Market valued for $2,447.83 million in 2021 and is estimated to reach $5,692.53 million by 2031, exhibiting a CAGR of 8.8% from 2022 to 2031. 

Mitral valve is an essential component of the heart's circulatory system that is located on the left side of the heart between the left atrium and left ventricle. It is responsible for regulating the flow of blood from the left atrium into the left ventricle. When the mitral valve is diseased or damaged, it can lead to a range of problems that can affect the heart's ability to pump blood efficiently. Common mitral valve conditions include mitral valve stenosis, mitral valve prolapse, and mitral valve regurgitation.

For example, if the valve is narrowed, the amount of blood that can flow from the left atrium into the left ventricle is reduced, which can cause the left atrium to enlarge, thus increasing the pressure in lungs. These conditions can lead to symptoms such as shortness of breath, fatigue, and chest pain. In some cases, the valve is not able to close properly, causing the blood to flow back into the atrium, which can lead to similar symptoms. In both cases, treatment may involve medication or therapeutics to manage symptoms, but in severe cases, surgery may be required to repair or replace the valve. In some cases of mitral valve regurgitation, cardiac resynchronization therapy may be used to treat the condition.

The major factor driving the growth of mitral valve disease market is increase in prevalence of mitral valve diseases. Alarming increase has been witnessed in the number of patients diagnosed with mitral valve diseases such as mitral regurgitation, mitral prolapse, and mitral stenosis. For instance, Journal of Clinical Medicine 2022 stated that mitral regurgitation is the second most common valvular heart disease in Europe and the most common in the U.S., with a prevalence of 9.3% in the population aged over 75 years. Thus, rise in prevalence of mitral valve diseases such as mitral stenosis, mitral prolapse, and mitral regurgitation escalates the demand for various treatment options, including therapeutics, repair, and replacement surgeries and cardiac synchronization therapy, which, in turn, contributes toward the growth of the global mitral valve disease market. 

In addition, technological advancements have played a significant role in driving the market growth in recent years. As the prevalence of mitral valve diseases rises, the demand for better treatment options that can provide improved outcomes and reduced recovery times increases simultaneously. One of the most significant technological advancements in this field is the development of minimally invasive techniques such as transcatheter mitral valve replacement (TMVR). This technique involves replacing the diseased valve with an artificial valve through a small incision in the groin or chest. This offers several advantages over traditional open-heart surgery, such as reduced recovery time and lower risk of complications. Thus, huge demand for technologically advanced mitral valve treatment devices in the healthcare sector fuels the growth of the market. 

Furthermore, surge in geriatric population drives the demand for mitral valve disease treatments around the globe, owing to the fact that aged individuals are highly susceptible to mitral valve diseases. Moreover, with growing age , the valve can be damaged or weakened, making it more prone to malfunction. In addition, rise in risk factors such as high blood pressure and obesity can increase the risk of developing mitral valve disease, which is anticipated to foster the growth of mitral valve disease market.

However, the cost of mitral valve treatment procedures such as repair, replacement, and cardiac synchronization therapy is significantly high, which acts as a barrier for the market growth. In addition, low awareness among the population in underdeveloped countries regarding the available treatments hinders the market growth. Moreover, stringent regulations by the governing bodies for the development and launching of mitral valve treatment products may indeed be a hindrance to market growth. 

On the contrary, increase in demand for advanced healthcare services, rise in awareness of mitral valve treatment medications & procedures, and government investments in healthcare infrastructure are expected to provide remunerative opportunities for the expansion of the market during the forecast period. Governments in Asia-Pacific and LAMEA are substantially investing in the development of healthcare infrastructure and increasing the access to healthcare services, which notably drive the growth of the mitral valve disease market.

The global mitral valve disease market is segmented into treatment type, indication, end user, and region. On the basis of treatment type, the market is fragmented into mitral valve repair, mitral valve replacement, cardiac resynchronization therapy (CRT), and mitral valve therapeutics. The mitral valve replacement segment is further bifurcated into mechanical valves and biological valves (bioprosthetic tissue). On the other hand, the mitral valve therapeutics segment is subdivided into beta blockers, diuretics, anticoagulants, and others. 

Depending on indication, the market is fragmented into mitral valve stenosis, mitral valve prolapse, and mitral valve regurgitation. Furthermore, mitral valve regurgitation segment is bifurcated into primary (degenerative) mitral valve regurgitation and secondary (functional) mitral valve regurgitation. By end user, the market is segregated into hospitals, ambulatory surgical centers, and others.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

The major players that operate in the mitral valve disease market include Valcare Medical, Affluent Medical, Abbott Laboratories, Corcym UK Limited, Edwards Lifesciences Corporation, Medtronic Plc., ShockWave Medical, Inc., Artivion, Inc., Labcor Laboratorios Ltda, Braile Biomédica, Zydus Lifesciences Limited, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Bayer AG, and Novartis AG.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mitral valve disease market analysis from 2021 to 2031 to identify the prevailing mitral valve disease market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the mitral valve disease market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global mitral valve disease market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Treatment Type

Mitral Valve Repair
Mitral Valve Replacement
Product Type
Mechanical Valves
Biological Valves
Cardiac Resynchronization Therapy
Mitral Valve Therapeutics
Drug Class
Beta blockers
Diuretics
Anticoagulants
Others

By Indication

Mitral Valve Stenosis
Mitral Valve Prolapse
Mitral Valve Regurgitation
Type
Primary Mitral Valve Regurgitation
Secondary Mitral Valve Regurgitation

By End User

Hospitals
Ambulatory Surgical Centers
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Bayer AG
Zydus Lifesciences Limited
Affluent Medical
Artivion, Inc.
Valcare Medical
Corcym UK Limited
Pfizer Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.
Medtronic plc
ShockWave Medical, Inc.
Braile Biomedica
Abbott Laboratories
Labcor Laboratorios Ltda
Edwards Lifesciences Corporation

Please Note: It will take 7-10 business days to complete the report upon order confirmation.